Korean Drug Co. Ltd (014570) — Capital Reinvestment Ratio

Latest as of September 2025: 0.02x

Korean Drug Co. Ltd (014570) has a Capital Reinvestment Ratio of 0.02x as of September 2025, meaning it reinvests 0% of its operating cash flow (₩3.72 Billion) in capital expenditures (₩67.38 Million). See Korean Drug Co. Ltd balance sheet quality to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

0.02x
Capex / Operating Cash Flow

Operating Cash Flow

₩3.72 Billion
KRW

Capital Expenditures

₩67.38 Million
KRW

Data as of

Sep 2025
Most recent filing

Korean Drug Co. Ltd Capital Reinvestment Ratio (2014–2024)

This chart tracks Korean Drug Co. Ltd's Capital Reinvestment Ratio across 10 annual periods. Check Korean Drug Co. Ltd total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.

Annual Capital Reinvestment Ratio for Korean Drug Co. Ltd (2014–2024)

Year-by-year Capital Reinvestment Ratio for Korean Drug Co. Ltd from 2014 to 2024. For live market cap and broader valuation context, see Korean Drug Co. Ltd market cap and net worth.

Year Reinvestment Ratio Operating CF (KRW) Capital Expenditures YoY Change
2024 0.21x ₩4.87 Billion ₩1.04 Billion ▼ -79.2%
2022 1.03x ₩5.91 Billion ₩6.09 Billion ▲ +691.9%
2021 0.13x ₩8.81 Billion ₩1.15 Billion ▲ +117.3%
2020 0.06x ₩12.33 Billion ₩738.47 Million ▼ -87.8%
2019 0.49x ₩6.21 Billion ₩3.05 Billion ▲ +118.8%
2018 0.22x ₩5.79 Billion ₩1.30 Billion ▼ -91.1%
2017 2.53x ₩447.20 Million ₩1.13 Billion ▲ +2077.4%
2016 0.12x ₩3.96 Billion ₩460.84 Million ▼ -18.8%
2015 0.14x ₩6.13 Billion ₩878.05 Million ▲ +18.7%
2014 0.12x ₩4.46 Billion ₩538.19 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow